HAYWARD, Calif., Feb. 6 /PRNewswire/ -- This year marks 10 years of Guava Technologies bringing sophisticated, yet uniquely easy-to-use, cellular analysis technologies directly to the lab benches of thousands of scientists and clinicians worldwide. Since 1998, the company has experienced continued success, achieving several significant milestones, including introduction of the first commercial microcapillary flow cytometer and introduction of a low-cost automated cell counting system for monitoring treatment of HIV/AIDS in remote parts of the world.
Guava Technologies develops microcapillary flow cytometers, which accommodate smaller sample volumes, generate less waste, have lower operating costs, and are easier to set up and maintain than the typical traditional flow cytometer. By leveraging the unique attributes of microcapillary based flow cytometry, the company’s integrated systems enable scientists and clinicians not specialized in the technology to perform complex cellular analyses directly from their own lab bench -- quickly, simply, and cost-effectively. The company now has five systems and an ever-growing portfolio of reagents and assays on the market.
“We are exceptionally proud that virtually any scientist or clinician can learn to use a Guava System in less than one day,” said Lawrence Bruder, Chief Executive Officer. “We have made steady progress toward our goal of making flow cytometry -- an absolutely critical technology for cell analysis -- directly accessible to almost any scientist or clinician who could benefit from it.”
In addition, Guava Technologies has established a strong global sales and service organization with offices in Hayward, California, US, and Stamford, UK. “Truly believing that our customers come first, we have worked hard to ensure that we stand behind our products, and that our R&D efforts address our customers’ needs,” continued Mr. Bruder. The company’s user base now exceeds 1,300 users worldwide and continues to grow steadily.
“Our ten-year celebration provides an opportunity for us to reflect on where we’ve come from and establish new goals and initiatives that will continue to drive growth through the next decade and beyond,” said Mr. Bruder. “In 2007, we were recognized by Inc. Magazine as one of the fastest growing private companies in the US, and 2008 is certainly shaping up to be an equally, if not an even more, exciting year.”
Guava Technologies, Inc. (http://www.guavatechnologies.com) is a private biotechnology and medical device company that designs and manufactures easy-to-use, on-demand, benchtop cell analysis systems. In 2007, Guava Technologies achieved ISO13485 certification for the design and manufacture of medical devices. All Guava Systems are friendly, delivering turnkey assays that include optimized reagents and assay-specific software for applications such as cell counting/viability, antibody quantification, cell cycle, cytotoxicity, apoptosis, and more. Minimizing time from hypothesis to conclusion, Guava Systems are ideal for a broad range of medical and biomedical applications, and are helping scientists around the world understand life one cell at a time.
The Guava EasyCD4(R) System for monitoring treatment of HIV/AIDS is not available for sale in the US, EU, Japan, and some other countries; contact a Guava Technologies representative for availability in your region.
Guava, Guava Technologies Logo, and all other trademarks are property of Guava Technologies, Inc.
CONTACT: Lisa English, Communications Director of Guava Technologies,
Inc., +1-650-515-8514, lisa.english@guavatechnologies.com
Web site: http://www.guavatechnologies.com/
